Keros Therapeutics Proxy Fight: Stockholder Withholds Votes
Ticker: KROS · Form: DEFA14A · Filed: May 9, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | DEFA14A |
| Filed Date | May 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, shareholder-activism, board-of-directors
Related Tickers: KROS
TL;DR
Shareholder is withholding votes from Keros directors. Watch this space.
AI Summary
Keros Therapeutics, Inc. filed a DEFA14A proxy statement on May 9, 2025, related to a stockholder's announcement to withhold votes from two director nominees, Mary and David. This filing is a definitive proxy statement and does not require a filing fee.
Why It Matters
This filing indicates potential shareholder dissatisfaction or activism, which could influence board composition and future company strategy.
Risk Assessment
Risk Level: medium — Shareholder activism and potential board challenges can introduce uncertainty and impact stock price.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- Mary (person) — Director nominee
- David (person) — Director nominee
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, a Definitive Proxy Statement.
Who is the filing company?
The filing company is Keros Therapeutics, Inc.
What is the main subject of this filing?
The filing relates to a stockholder's announcement to withhold votes from two director nominees, Mary and David.
When was this filing made?
The filing was made on May 9, 2025.
Is there a filing fee associated with this document?
No, the filing states that no fee is required.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 9, 2025 by Mary regarding Keros Therapeutics, Inc. (KROS).